For 0 3 0 3 O
Part 4 8 4 8 O
A 9 10 9 10 O
( 11 12 11 12 O
LY2835219 12 21 12 21 B-treatment
+ 22 23 22 23 O
letrozole 24 33 24 33 B-treatment
): 33 35 33 35 O
Except 36 42 36 42 O
for 43 46 43 46 O
ongoing 47 54 47 54 O
therapy 55 62 55 62 B-treatment
with 63 67 63 67 I-treatment
letrozole 68 77 68 77 I-treatment
, 77 78 77 78 O
the 79 82 79 82 O
participant 83 94 83 94 O
must 95 99 95 99 O
not 100 103 100 103 O
have 104 108 104 108 O
received 109 117 109 117 O
prior 118 123 118 123 B-treatment
systemic 124 132 124 132 I-treatment
endocrine 133 142 133 142 I-treatment
therapy 143 150 143 150 I-treatment
for 151 154 151 154 O
metastatic 155 165 155 165 B-chronic_disease
disease 166 173 166 173 I-chronic_disease

For 0 3 174 177 O
Part 4 8 178 182 O
B 9 10 183 184 O
( 11 12 185 186 O
LY2835219 12 21 186 195 B-treatment
+ 22 23 196 197 O
anastrozole 24 35 198 209 B-treatment
): 35 37 209 211 O
Except 38 44 212 218 O
for 45 48 219 222 O
ongoing 49 56 223 230 O
therapy 57 64 231 238 B-treatment
with 65 69 239 243 I-treatment
anastrozole 70 81 244 255 I-treatment
, 81 82 255 256 O
the 83 86 257 260 O
participant 87 98 261 272 O
must 99 103 273 277 O
not 104 107 278 281 O
have 108 112 282 286 O
received 113 121 287 295 O
prior 122 127 296 301 B-treatment
systemic 128 136 302 310 I-treatment
endocrine 137 146 311 320 I-treatment
therapy 147 154 321 328 I-treatment
for 155 158 329 332 O
metastatic 159 169 333 343 B-chronic_disease
disease 170 177 344 351 I-chronic_disease

For 0 3 352 355 O
Part 4 8 356 360 O
C 9 10 361 362 O
( 11 12 363 364 O
LY2835219 12 21 364 373 B-treatment
+ 22 23 374 375 O
tamoxifen 24 33 376 385 B-treatment
): 33 35 385 387 O
The 36 39 388 391 O
participant 40 51 392 403 O
may 52 55 404 407 O
have 56 60 408 412 O
received 61 69 413 421 O
prior 70 75 422 427 B-treatment
systemic 76 84 428 436 I-treatment
endocrine 85 94 437 446 I-treatment
therapy 95 102 447 454 I-treatment
for 103 106 455 458 O
metastatic 107 117 459 469 B-cancer
disease 118 125 470 477 I-cancer
and 126 129 478 481 O
may 130 133 482 485 O
be 134 136 486 488 O
receiving 137 146 489 498 O
ongoing 147 154 499 506 B-treatment
therapy 155 162 507 514 I-treatment
with 163 167 515 519 I-treatment
tamoxifen 168 177 520 529 I-treatment

For 0 3 530 533 O
Part 4 8 534 538 O
D 9 10 539 540 O
( 11 12 541 542 O
LY2835219 12 21 542 551 B-treatment
+ 22 23 552 553 I-treatment
exemestane 24 34 554 564 I-treatment
): 34 36 564 566 O
The 37 40 567 570 O
participant 41 52 571 582 O
must 53 57 583 587 O
have 58 62 588 592 O
received 63 71 593 601 O
prior 72 77 602 607 B-treatment
systemic 78 86 608 616 I-treatment
endocrine 87 96 617 626 I-treatment
therapy 97 104 627 634 I-treatment
with 105 109 635 639 O
at 110 112 640 642 O
least 113 118 643 648 O
one 119 122 649 652 B-lower_bound
nonsteroidal 123 135 653 665 B-treatment
aromatase 136 145 666 675 I-treatment
inhibitor 146 155 676 685 I-treatment
( 156 157 686 687 O
anastrozole 157 168 687 698 B-treatment
, 168 169 698 699 O
letrozole 170 179 700 709 B-treatment
) 179 180 709 710 O
for 181 184 711 714 O
metastatic 185 195 715 725 B-cancer
disease 196 203 726 733 I-cancer
and 204 207 734 737 O
may 208 211 738 741 O
be 212 214 742 744 O
receiving 215 224 745 754 O
ongoing 225 232 755 762 O
therapy 233 240 763 770 B-treatment
with 241 245 771 775 I-treatment
exemestane 246 256 776 786 I-treatment

For 0 3 787 790 O
Part 4 8 791 795 O
E 9 10 796 797 O
( 11 12 798 799 O
LY2835219 12 21 799 808 O
+ 22 23 809 810 O
exemestane 24 34 811 821 B-treatment
+ 35 36 822 823 O
everolimus 37 47 824 834 B-treatment
): 47 49 834 836 O
The 50 53 837 840 O
participant 54 65 841 852 O
must 66 70 853 857 O
have 71 75 858 862 O
received 76 84 863 871 O
prior 85 90 872 877 B-treatment
systemic 91 99 878 886 I-treatment
endocrine 100 109 887 896 I-treatment
therapy 110 117 897 904 I-treatment
with 118 122 905 909 O
at 123 125 910 912 O
least 126 131 913 918 O
one 132 135 919 922 B-lower_bound
nonsteroidal 136 148 923 935 B-treatment
aromatase 149 158 936 945 I-treatment
inhibitor 159 168 946 955 I-treatment
( 169 170 956 957 O
anastrozole 170 181 957 968 B-treatment
, 181 182 968 969 O
letrozole 183 192 970 979 B-treatment
) 192 193 979 980 O
for 194 197 981 984 O
metastatic 198 208 985 995 B-cancer
disease 209 216 996 1003 I-cancer
and 217 220 1004 1007 O
may 221 224 1008 1011 O
be 225 227 1012 1014 O
receiving 228 237 1015 1024 O
ongoing 238 245 1025 1032 O
therapy 246 253 1033 1040 O
with 254 258 1041 1045 O
either 259 265 1046 1052 O
exemestane 266 276 1053 1063 O
or 277 279 1064 1066 O
exemestane 280 290 1067 1077 O
+ 291 292 1078 1079 O
everolimus 293 303 1080 1090 O

For 0 3 1091 1094 O
Part 4 8 1095 1099 O
F 9 10 1100 1101 O
( 11 12 1102 1103 O
LY2835219 12 21 1103 1112 B-treatment
+ 22 23 1113 1114 O
trastuzumab):The 24 40 1115 1131 B-treatment
participant 41 52 1132 1143 O
must 53 57 1144 1148 O
have 58 62 1149 1153 O
received 63 71 1154 1162 O
at 72 74 1163 1165 O
least 75 80 1166 1171 O
1 81 82 1172 1173 O
chemotherapy 83 95 1174 1186 B-treatment
regimen 96 103 1187 1194 I-treatment
for 104 107 1195 1198 O
metastatic 108 118 1199 1209 B-cancer
disease 119 126 1210 1217 I-cancer
and 127 130 1218 1221 O
may 131 134 1222 1225 O
be 135 137 1226 1228 O
receiving 138 147 1229 1238 O
ongoing 148 155 1239 1246 O
therapy 156 163 1247 1254 B-treatment
with 164 168 1255 1259 I-treatment
trastuzumab 169 180 1260 1271 I-treatment

For 0 3 1272 1275 O
Part 4 8 1276 1280 O
F 9 10 1281 1282 O
and 11 14 1283 1286 O
H 15 16 1287 1288 O
: 16 17 1288 1289 O
concurrent 18 28 1290 1300 O
treatment 29 38 1301 1310 B-treatment
with 39 43 1311 1315 O
trastuzumab 44 55 1316 1327 B-treatment
emtansine 56 65 1328 1337 I-treatment
( 66 67 1338 1339 I-treatment
T 67 68 1339 1340 I-treatment
- 68 69 1340 1341 I-treatment
DM1 69 72 1341 1344 I-treatment
) 72 73 1344 1345 I-treatment

For 0 3 1346 1349 O
Part 4 8 1350 1354 O
G 9 10 1355 1356 O
( 11 12 1357 1358 O
abemaciclib 12 23 1358 1369 B-treatment
+ 24 25 1370 1371 O
LY3023414 26 35 1372 1381 B-treatment
+ 36 37 1382 1383 O
fulvestrant 38 49 1384 1395 B-treatment
): 49 51 1395 1397 O
The 52 55 1398 1401 O
participant 56 67 1402 1413 O
may 68 71 1414 1417 O
have 72 76 1418 1422 O
received 77 85 1423 1431 O
prior 86 91 1432 1437 B-treatment
systemic 92 100 1438 1446 I-treatment
endocrine 101 110 1447 1456 I-treatment
therapy 111 118 1457 1464 I-treatment
with 119 123 1465 1469 O
at 124 126 1470 1472 O
least 127 132 1473 1478 O
one 133 136 1479 1482 B-lower_bound
nonsteroidal 137 149 1483 1495 B-treatment
aromatase 150 159 1496 1505 I-treatment
inhibitor 160 169 1506 1515 I-treatment
( 170 171 1516 1517 O
anastrozole 171 182 1517 1528 B-treatment
, 182 183 1528 1529 O
letrozole 184 193 1530 1539 B-treatment
) 193 194 1539 1540 O
for 195 198 1541 1544 O
metastatic 199 209 1545 1555 B-cancer
disease 210 217 1556 1563 I-cancer

For 0 3 1564 1567 O
Part 4 8 1568 1572 O
G 9 10 1573 1574 O
, 10 11 1574 1575 O
H 12 13 1576 1577 O
, 13 14 1577 1578 O
and 15 18 1579 1582 O
I 19 20 1583 1584 O
: 20 21 1584 1585 O
Have 22 26 1586 1590 O
measureable 27 38 1591 1602 B-chronic_disease
disease 39 46 1603 1610 I-chronic_disease
as 47 49 1611 1613 O
defined 50 57 1614 1621 O
by 58 60 1622 1624 O
RECIST 61 67 1625 1631 O
1.1 68 71 1632 1635 O

For 0 3 1636 1639 O
Part 4 8 1640 1644 O
G 9 10 1645 1646 O
: 10 11 1646 1647 O
Have 12 16 1648 1652 O
a 17 18 1653 1654 O
baseline 19 27 1655 1663 O
electrocardiogram 28 45 1664 1681 B-treatment
( 46 47 1682 1683 O
obtained 47 55 1683 1691 O
from 56 60 1692 1696 O
Day 61 64 1697 1700 O
-14 65 68 1701 1704 O
to 69 71 1705 1707 O
Day 72 75 1708 1711 O
-1 76 78 1712 1714 O
) 78 79 1714 1715 O
with 80 84 1716 1720 O
any 85 88 1721 1724 O
of 89 91 1725 1727 O
the 92 95 1728 1731 O
following 96 105 1732 1741 O
abnormal 106 114 1742 1750 O
findings 115 123 1751 1759 O
: 123 124 1759 1760 O
ventricular 125 136 1761 1772 B-chronic_disease
arrhythmia 137 147 1773 1783 I-chronic_disease
, 147 148 1783 1784 O
evidence 149 157 1785 1793 O
of 158 160 1794 1796 O
acute 161 166 1797 1802 O
myocardial 167 177 1803 1813 B-chronic_disease
ischemia 178 186 1814 1822 I-chronic_disease
, 186 187 1822 1823 O
heart 188 193 1824 1829 B-chronic_disease
block 194 199 1830 1835 I-chronic_disease
( 200 201 1836 1837 O
of 201 203 1837 1839 O
any 204 207 1840 1843 O
degree 208 214 1844 1850 O
) 214 215 1850 1851 O
, 215 216 1851 1852 O
or 217 219 1853 1855 O
QTc 220 223 1856 1859 O
prolongation 224 236 1860 1872 O
( 237 238 1873 1874 O
defined 238 245 1874 1881 O
as 246 248 1882 1884 O
QTcB 249 253 1885 1889 B-clinical_variable
≥450 254 258 1890 1894 O
milliseconds 259 271 1895 1907 I-lower_bound
) 271 272 1907 1908 O

For 0 3 1909 1912 O
Part 4 8 1913 1917 O
G 9 10 1918 1919 O
: 10 11 1919 1920 O
Have 12 16 1921 1925 O
type 17 21 1926 1930 B-chronic_disease
1 22 23 1931 1932 I-chronic_disease
diabetes 24 32 1933 1941 I-chronic_disease
mellitus 33 41 1942 1950 I-chronic_disease
or 42 44 1951 1953 O
a 45 46 1954 1955 O
history 47 54 1956 1963 O
of 55 57 1964 1966 O
gestational 58 69 1967 1978 B-chronic_disease
diabetes 70 78 1979 1987 I-chronic_disease
mellitus 79 87 1988 1996 I-chronic_disease

For 0 3 1997 2000 O
Part 4 8 2001 2005 O
H 9 10 2006 2007 O
: 10 11 2007 2008 O
( 12 13 2009 2010 O
abemaciclib 13 24 2010 2021 B-treatment
+ 25 26 2022 2023 O
trastuzumab 27 38 2024 2035 B-treatment
+ 39 40 2036 2037 O
pertuzumab 41 51 2038 2048 B-treatment
): 51 53 2048 2050 O
The 54 57 2051 2054 O
participant 58 69 2055 2066 O
must 70 74 2067 2071 O
have 75 79 2072 2076 O
received 80 88 2077 2085 O
at 89 91 2086 2088 O
least 92 97 2089 2094 O
1 98 99 2095 2096 B-lower_bound
chemotherapy 100 112 2097 2109 B-treatment
regimen 113 120 2110 2117 I-treatment
for 121 124 2118 2121 O
metastatic 125 135 2122 2132 B-cancer
disease 136 143 2133 2140 I-cancer

For 0 3 2141 2144 O
Part 4 8 2145 2149 O
I 9 10 2150 2151 O
( 11 12 2152 2153 O
abemaciclib 12 23 2153 2164 B-treatment
+ 24 25 2165 2166 I-treatment
endocrine 26 35 2167 2176 I-treatment
therapy 36 43 2177 2184 I-treatment
): 43 45 2184 2186 O
The 46 49 2187 2190 O
participant 50 61 2191 2202 O
must 62 66 2203 2207 O
have 67 71 2208 2212 O
demonstrated 72 84 2213 2225 O
evidence 85 93 2226 2234 O
of 94 96 2235 2237 O
disease 97 104 2238 2245 O
progression 105 116 2246 2257 O
on 117 119 2258 2260 O
a 120 121 2261 2262 O
Cyclin 122 128 2263 2269 B-clinical_variable
Dependent 129 138 2270 2279 I-clinical_variable
Kinase 139 145 2280 2286 I-clinical_variable
4 146 147 2287 2288 I-clinical_variable
( 148 149 2289 2290 I-clinical_variable
CDK4 149 153 2290 2294 I-clinical_variable
) 153 154 2294 2295 I-clinical_variable
and 155 158 2296 2299 O
Cyclin 159 165 2300 2306 B-treatment
Dependent 166 175 2307 2316 I-treatment
Kinase 176 182 2317 2323 I-treatment
6 183 184 2324 2325 I-treatment
( 185 186 2326 2327 I-treatment
CDK6 186 190 2327 2331 I-treatment
) 190 191 2331 2332 I-treatment
inhibitor 192 201 2333 2342 I-treatment
( 202 203 2343 2344 O
either 203 209 2344 2350 O
palbociclib 210 221 2351 2362 B-treatment
or 222 224 2363 2365 O
ribociclib 225 235 2366 2376 B-treatment
) 235 236 2376 2377 O
plus 237 241 2378 2382 O
endocrine 242 251 2383 2392 O
therapy 252 259 2393 2400 O
for 260 263 2401 2404 O
advanced 264 272 2405 2413 O
or 273 275 2414 2416 O
metastatic 276 286 2417 2427 B-cancer
disease 287 294 2428 2435 I-cancer
as 295 297 2436 2438 O
the 298 301 2439 2442 O
most 302 306 2443 2447 O
recent 307 313 2448 2454 O
therapy 314 321 2455 2462 O
immediately 322 333 2463 2474 O
preceding 334 343 2475 2484 O
study 344 349 2485 2490 O
entry 350 355 2491 2496 O

For 0 3 2497 2500 O
Parts 4 9 2501 2506 O
A 10 11 2507 2508 O
, 11 12 2508 2509 O
B 13 14 2510 2511 O
, 14 15 2511 2512 O
C 16 17 2513 2514 O
, 17 18 2514 2515 O
D 19 20 2516 2517 O
, 20 21 2517 2518 O
E 22 23 2519 2520 O
, 23 24 2520 2521 O
F 25 26 2522 2523 O
, 26 27 2523 2524 O
H 28 29 2525 2526 O
: 29 30 2526 2527 O
Have 31 35 2528 2532 O
received 36 44 2533 2541 O
prior 45 50 2542 2547 B-treatment
therapy 51 58 2548 2555 I-treatment
with 59 63 2556 2560 I-treatment
a 64 65 2561 2562 I-treatment
CDK4/6 66 72 2563 2569 I-treatment
inhibitor 73 82 2570 2579 I-treatment

For 0 3 2580 2583 O
Parts 4 9 2584 2589 O
A 10 11 2590 2591 O
, 11 12 2591 2592 O
B 13 14 2593 2594 O
, 14 15 2594 2595 O
C 16 17 2596 2597 O
, 17 18 2597 2598 O
D 19 20 2599 2600 O
, 20 21 2600 2601 O
E 22 23 2602 2603 O
, 23 24 2603 2604 O
G 25 26 2605 2606 O
and 27 30 2607 2610 O
I 31 32 2611 2612 O
: 32 33 2612 2613 O
Have 34 38 2614 2618 O
received 39 47 2619 2627 O
prior 48 53 2628 2633 B-treatment
systemic 54 62 2634 2642 I-treatment
chemotherapy 63 75 2643 2655 I-treatment
for 76 79 2656 2659 O
metastatic 80 90 2660 2670 B-cancer
disease 91 98 2671 2678 O

For 0 3 2679 2682 O
Parts 4 9 2683 2688 O
A 10 11 2689 2690 O
, 11 12 2690 2691 O
B 13 14 2692 2693 O
, 14 15 2693 2694 O
C 16 17 2695 2696 O
, 17 18 2696 2697 O
D 19 20 2698 2699 O
, 20 21 2699 2700 O
E 22 23 2701 2702 O
, 23 24 2702 2703 O
and 25 28 2704 2707 O
F 29 30 2708 2709 O
: 30 31 2709 2710 O
Have 32 36 2711 2715 O
either 37 43 2716 2722 O
measureable 44 55 2723 2734 O
disease 56 63 2735 2742 O
or 64 66 2743 2745 O
nonmeasureable 67 81 2746 2760 O
but 82 85 2761 2764 O
evaluable 86 95 2765 2774 O
bone 96 100 2775 2779 B-chronic_disease
disease 101 108 2780 2787 I-chronic_disease
as 109 111 2788 2790 O
defined 112 119 2791 2798 O
by 120 122 2799 2801 O
the 123 126 2802 2805 O
Response 127 135 2806 2814 O
Evaluation 136 146 2815 2825 O
Criteria 147 155 2826 2834 O
in 156 158 2835 2837 O
Solid 159 164 2838 2843 O
Tumors 165 171 2844 2850 O
( 172 173 2851 2852 O
RECIST 173 179 2852 2858 O
1.1 180 183 2859 2862 O
) 183 184 2862 2863 O

For 0 3 2864 2867 O
Parts 4 9 2868 2873 O
F 10 11 2874 2875 O
and 12 15 2876 2879 O
H 16 17 2880 2881 O
: 17 18 2881 2882 O
Cardiac 19 26 2883 2890 B-chronic_disease
disease 27 34 2891 2898 I-chronic_disease
including 35 44 2899 2908 O
myocardial 45 55 2909 2919 B-chronic_disease
infarction 56 66 2920 2930 I-chronic_disease
within 67 73 2931 2937 O
6 74 75 2938 2939 B-upper_bound
months 76 82 2940 2946 I-upper_bound
, 82 83 2946 2947 O
unstable 84 92 2948 2956 B-chronic_disease
angina 93 99 2957 2963 I-chronic_disease
, 99 100 2963 2964 O
or 101 103 2965 2967 O
New 104 107 2968 2971 B-clinical_variable
York 108 112 2972 2976 I-clinical_variable
Heart 113 118 2977 2982 I-clinical_variable
Association 119 130 2983 2994 I-clinical_variable
( 131 132 2995 2996 I-clinical_variable
NYHA 132 136 2996 3000 I-clinical_variable
) 136 137 3000 3001 I-clinical_variable
Grade 138 143 3002 3007 B-lower_bound
II 144 146 3008 3010 I-lower_bound
or 147 149 3011 3013 O
greater 150 157 3014 3021 O
functional 158 168 3022 3032 B-chronic_disease
impairment 169 179 3033 3043 I-chronic_disease

Have 0 4 3044 3048 O
a 5 6 3049 3050 O
diagnosis 7 16 3051 3060 O
of 17 19 3061 3063 O
hormone 20 27 3064 3071 B-cancer
receptor 28 36 3072 3080 I-cancer
positive 37 45 3081 3089 I-cancer
( 46 47 3090 3091 I-cancer
HR+ 47 50 3091 3094 I-cancer
) 50 51 3094 3095 I-cancer
, 51 52 3095 3096 O
human 53 58 3097 3102 B-cancer
epidermal 59 68 3103 3112 I-cancer
growth 69 75 3113 3119 I-cancer
factor 76 82 3120 3126 I-cancer
receptor 83 91 3127 3135 I-cancer
2 92 93 3136 3137 I-cancer
( 94 95 3138 3139 I-cancer
HER2 95 99 3139 3143 I-cancer
) 99 100 3143 3144 I-cancer
negative 101 109 3145 3153 O
metastatic 110 120 3154 3164 B-cancer
breast 121 127 3165 3171 I-cancer
cancer 128 134 3172 3178 I-cancer
for 135 138 3179 3182 O
Parts 139 144 3183 3188 O
A 145 146 3189 3190 O
to 147 149 3191 3193 O
E 150 151 3194 3195 O
, 151 152 3195 3196 O
G 153 154 3197 3198 O
, 154 155 3198 3199 O
and 156 159 3200 3203 O
I 160 161 3204 3205 O

Have 0 4 3206 3210 O
a 5 6 3211 3212 O
diagnosis 7 16 3213 3222 O
of 17 19 3223 3225 O
human 20 25 3226 3231 O
epidermal 26 35 3232 3241 O
growth 36 42 3242 3248 O
factor 43 49 3249 3255 O
receptor 50 58 3256 3264 O
2 59 60 3265 3266 O
( 61 62 3267 3268 O
HER2 62 66 3268 3272 B-clinical_variable
) 66 67 3272 3273 O
positive 68 76 3274 3282 O
metastatic 77 87 3283 3293 B-cancer
breast 88 94 3294 3300 I-cancer
cancer 95 101 3301 3307 I-cancer
for 102 105 3308 3311 O
Parts 106 111 3312 3317 O
F 112 113 3318 3319 O
and 114 117 3320 3323 O
H 118 119 3324 3325 O

Have 0 4 3326 3330 O
a 5 6 3331 3332 O
performance 7 18 3333 3344 B-clinical_variable
status 19 25 3345 3351 I-clinical_variable
of 26 28 3352 3354 O
≤1 29 31 3355 3357 O
on 32 34 3358 3360 O
the 35 38 3361 3364 O
Eastern 39 46 3365 3372 B-clinical_variable
Cooperative 47 58 3373 3384 I-clinical_variable
Oncology 59 67 3385 3393 I-clinical_variable
Group 68 73 3394 3399 I-clinical_variable
( 74 75 3400 3401 I-clinical_variable
ECOG 75 79 3401 3405 I-clinical_variable
) 79 80 3405 3406 I-clinical_variable
scale 81 86 3407 3412 I-clinical_variable

Have 0 4 3413 3417 O
brain 5 10 3418 3423 B-cancer
metastasis 11 21 3424 3434 I-cancer
without 22 29 3435 3442 O
prior 30 35 3443 3448 B-treatment
radiotherapy 36 48 3449 3461 I-treatment

Have 0 4 3462 3466 O
central 5 12 3467 3474 B-cancer
nervous 13 20 3475 3482 I-cancer
system 21 27 3483 3489 I-cancer
( 28 29 3490 3491 I-cancer
CNS 29 32 3491 3494 I-cancer
) 32 33 3494 3495 I-cancer
metastasis 34 44 3496 3506 I-cancer
with 45 49 3507 3511 O
either 50 56 3512 3518 O
radiotherapy 57 69 3519 3531 B-treatment
or 70 72 3532 3534 O
development 73 84 3535 3546 O
of 85 87 3547 3549 O
neurological 88 100 3550 3562 O
changes 101 108 3563 3570 O
≤14 109 112 3571 3574 O
days 113 117 3575 3579 I-upper_bound
prior 118 123 3580 3585 I-upper_bound
to 124 126 3586 3588 O
receiving 127 136 3589 3598 O
study 137 142 3599 3604 O
treatment 143 152 3605 3614 B-treatment

Have 0 4 3615 3619 O
discontinued 5 17 3620 3632 O
all 18 21 3633 3636 O
previous 22 30 3637 3645 B-treatment
therapies 31 40 3646 3655 I-treatment
for 41 44 3656 3659 O
breast 45 51 3660 3666 B-cancer
cancer 52 58 3667 3673 I-cancer
( 59 60 3674 3675 O
including 60 69 3675 3684 O
chemotherapy 70 82 3685 3697 B-treatment
, 82 83 3697 3698 O
radiotherapy 84 96 3699 3711 B-treatment
, 96 97 3711 3712 O
immunotherapy 98 111 3713 3726 B-treatment
, 111 112 3726 3727 O
and 113 116 3728 3731 O
investigational 117 132 3732 3747 B-treatment
therapy 133 140 3748 3755 I-treatment
) 140 141 3755 3756 O
, 141 142 3756 3757 O
except 143 149 3758 3764 O
for 150 153 3765 3768 O
ongoing 154 161 3769 3776 O
corresponding 162 175 3777 3790 O
combination 176 187 3791 3802 B-treatment
therapy 188 195 3803 3810 I-treatment
, 195 196 3810 3811 O
for 197 200 3812 3815 O
at 201 203 3816 3818 O
least 204 209 3819 3824 O
21 210 212 3825 3827 B-lower_bound
days 213 217 3828 3832 I-lower_bound
for 218 221 3833 3836 O
myelosuppressive 222 238 3837 3853 B-treatment
agents 239 245 3854 3860 I-treatment
or 246 248 3861 3863 O
14 249 251 3864 3866 B-lower_bound
days 252 256 3867 3871 I-lower_bound
for 257 260 3872 3875 O
nonmyelosuppressive 261 280 3876 3895 B-treatment
agents 281 287 3896 3902 I-treatment
prior 288 293 3903 3908 O
to 294 296 3909 3911 O
receiving 297 306 3912 3921 O
study 307 312 3922 3927 B-treatment
drug(s 313 319 3928 3934 I-treatment
) 319 320 3934 3935 I-treatment
, 320 321 3935 3936 O
and 322 325 3937 3940 O
recovered 326 335 3941 3950 O
from 336 340 3951 3955 O
the 341 344 3956 3959 O
acute 345 350 3960 3965 O
effects 351 358 3966 3973 O
of 359 361 3974 3976 O
therapy 362 369 3977 3984 O
( 370 371 3985 3986 O
until 371 376 3986 3991 O
the 377 380 3992 3995 O
toxicity 381 389 3996 4004 O
resolves 390 398 4005 4013 O
to 399 401 4014 4016 O
either 402 408 4017 4023 O
baseline 409 417 4024 4032 O
or 418 420 4033 4035 O
at 421 423 4036 4038 O
least 424 429 4039 4044 O
Grade 430 435 4045 4050 B-lower_bound
1 436 437 4051 4052 I-lower_bound
) 437 438 4052 4053 O

Have 0 4 4054 4058 O
metastatic 5 15 4059 4069 B-cancer
breast 16 22 4070 4076 I-cancer
cancer 23 29 4077 4083 I-cancer
with 30 34 4084 4088 O
severe 35 41 4089 4095 O
organ 42 47 4096 4101 O
dysfunction 48 59 4102 4113 O
as 60 62 4114 4116 O
assessed 63 71 4117 4125 O
by 72 74 4126 4128 O
symptoms 75 83 4129 4137 O
and 84 87 4138 4141 O
signs 88 93 4142 4147 O
, 93 94 4147 4148 O
laboratory 95 105 4149 4159 O
studies 106 113 4160 4167 O
, 113 114 4167 4168 O
and 115 118 4169 4172 O
rapid 119 124 4173 4178 O
progression 125 136 4179 4190 O
of 137 139 4191 4193 O
the 140 143 4194 4197 O
disease 144 151 4198 4205 O

Have 0 4 4206 4210 O
serious 5 12 4211 4218 O
preexisting 13 24 4219 4230 O
medical 25 32 4231 4238 O
conditions 33 43 4239 4249 O
that 44 48 4250 4254 O
, 48 49 4254 4255 O
in 50 52 4256 4258 O
the 53 56 4259 4262 O
judgment 57 65 4263 4271 O
of 66 68 4272 4274 O
the 69 72 4275 4278 O
investigator 73 85 4279 4291 O
, 85 86 4291 4292 O
would 87 92 4293 4298 O
preclude 93 101 4299 4307 O
participation 102 115 4308 4321 O
in 116 118 4322 4324 O
this 119 123 4325 4329 O
study 124 129 4330 4335 O
( 130 131 4336 4337 O
for 131 134 4337 4340 O
example 135 142 4341 4348 O
, 142 143 4348 4349 O
history 144 151 4350 4357 O
of 152 154 4358 4360 O
major 155 160 4361 4366 B-treatment
surgical 161 169 4367 4375 I-treatment
resection 170 179 4376 4385 I-treatment
involving 180 189 4386 4395 I-treatment
the 190 193 4396 4399 I-treatment
stomach 194 201 4400 4407 I-treatment
or 202 204 4408 4410 I-treatment
small 205 210 4411 4416 I-treatment
bowel 211 216 4417 4422 I-treatment
) 216 217 4422 4423 O

Hematologic 0 11 4424 4435 O
: 11 12 4435 4436 O
Absolute 13 21 4437 4445 B-clinical_variable
neutrophil 22 32 4446 4456 I-clinical_variable
count 33 38 4457 4462 I-clinical_variable
( 39 40 4463 4464 I-clinical_variable
ANC 40 43 4464 4467 I-clinical_variable
) 43 44 4467 4468 I-clinical_variable
≥1.5 45 49 4469 4473 O
x 50 51 4474 4475 I-lower_bound
10 52 54 4476 4478 I-lower_bound
^ 54 55 4478 4479 I-lower_bound
9 55 56 4479 4480 I-lower_bound
/ 56 57 4480 4481 I-lower_bound
liter 57 62 4481 4486 I-lower_bound
( 63 64 4487 4488 I-lower_bound
L 64 65 4488 4489 I-lower_bound
) 65 66 4489 4490 I-lower_bound
, 66 67 4490 4491 O
platelets 68 77 4492 4501 B-clinical_variable
≥ 78 79 4502 4503 O
100 80 83 4504 4507 B-lower_bound
x 84 85 4508 4509 I-lower_bound
10 86 88 4510 4512 I-lower_bound
^ 88 89 4512 4513 I-lower_bound
9 89 90 4513 4514 I-lower_bound
/ 90 91 4514 4515 I-lower_bound
L 91 92 4515 4516 I-lower_bound
, 92 93 4516 4517 O
and 94 97 4518 4521 O
hemoglobin 98 108 4522 4532 B-clinical_variable
≥ 109 110 4533 4534 O
8 111 112 4535 4536 B-lower_bound
gram 113 117 4537 4541 I-lower_bound
/ 117 118 4541 4542 I-lower_bound
deciliter 118 127 4542 4551 I-lower_bound
( 128 129 4552 4553 I-lower_bound
g 129 130 4553 4554 I-lower_bound
/ 130 131 4554 4555 I-lower_bound
dL 131 133 4555 4557 I-lower_bound
) 133 134 4557 4558 I-lower_bound

Hepatic 0 7 4559 4566 O
: 7 8 4566 4567 O
Bilirubin 9 18 4568 4577 B-clinical_variable
≤1.5 19 23 4578 4582 O
times 24 29 4583 4588 I-upper_bound
upper 30 35 4589 4594 I-upper_bound
limits 36 42 4595 4601 I-upper_bound
of 43 45 4602 4604 I-upper_bound
normal 46 52 4605 4611 I-upper_bound
( 53 54 4612 4613 I-upper_bound
ULN 54 57 4613 4616 I-upper_bound
) 57 58 4616 4617 I-upper_bound
, 58 59 4617 4618 O
alanine 60 67 4619 4626 B-clinical_variable
aminotransferase 68 84 4627 4643 I-clinical_variable
( 85 86 4644 4645 I-clinical_variable
ALT 86 89 4645 4648 I-clinical_variable
) 89 90 4648 4649 I-clinical_variable
≤ 91 92 4650 4651 O
3.0 93 96 4652 4655 B-upper_bound
times 97 102 4656 4661 I-upper_bound
ULN 103 106 4662 4665 I-upper_bound

Part 0 4 4666 4670 O
G 5 6 4671 4672 O
: 6 7 4672 4673 O
Have 8 12 4674 4678 O
received 13 21 4679 4687 O
prior 22 27 4688 4693 B-treatment
therapy 28 35 4694 4701 I-treatment
with 36 40 4702 4706 I-treatment
fulvestrant 41 52 4707 4718 I-treatment
or 53 55 4719 4721 I-treatment
any 56 59 4722 4725 I-treatment
PI3 60 63 4726 4729 I-treatment
K 63 64 4729 4730 I-treatment
and/or 65 71 4731 4737 I-treatment
mTOR 72 76 4738 4742 I-treatment
inhibitor 77 86 4743 4752 I-treatment
( 87 88 4753 4754 I-treatment
including 88 97 4754 4763 I-treatment
LY3023414 98 107 4764 4773 I-treatment
) 107 108 4773 4774 I-treatment

Part 0 4 4775 4779 O
I 5 6 4780 4781 O
: 6 7 4781 4782 O
Have 8 12 4783 4787 O
received 13 21 4788 4796 O
prior 22 27 4797 4802 B-treatment
treatment 28 37 4803 4812 I-treatment
with 38 42 4813 4817 I-treatment
abemaciclib 43 54 4818 4829 I-treatment
in 55 57 4830 4832 O
any 58 61 4833 4836 O
setting 62 69 4837 4844 O

Participants 0 12 4845 4857 O
may 13 16 4858 4861 O
be 17 19 4862 4864 O
receiving 20 29 4865 4874 O
a 30 31 4875 4876 O
stable 32 38 4877 4883 O
dose 39 43 4884 4888 O
of 44 46 4889 4891 O
corticosteroids 47 62 4892 4907 B-treatment

Parts 0 5 4908 4913 O
H 6 7 4914 4915 O
, 7 8 4915 4916 O
and 9 12 4917 4920 O
I 13 14 4921 4922 O
: 14 15 4922 4923 O
Must 16 20 4924 4928 O
be 21 23 4929 4931 O
able 24 28 4932 4936 O
and 29 32 4937 4940 O
willing 33 40 4941 4948 O
to 41 43 4949 4951 O
undergo 44 51 4952 4959 O
mandatory 52 61 4960 4969 O
tumor 62 67 4970 4975 B-cancer
biopsies 68 76 4976 4984 O
prior 77 82 4985 4990 O
to 83 85 4991 4993 O
study 86 91 4994 4999 O
treatment 92 101 5000 5009 B-treatment
and 102 105 5010 5013 O
at 106 108 5014 5016 O
the 109 112 5017 5020 O
time 113 117 5021 5025 O
of 118 120 5026 5028 O
discontinuation 121 136 5029 5044 O
from 137 141 5045 5049 O
study 142 147 5050 5055 O
treatment 148 157 5056 5065 O

Renal 0 5 5066 5071 O
: 5 6 5071 5072 O
Serum 7 12 5073 5078 B-clinical_variable
creatinine 13 23 5079 5089 I-clinical_variable
≤ 24 25 5090 5091 O
1.5 26 29 5092 5095 B-upper_bound
times 30 35 5096 5101 I-upper_bound
ULN 36 39 5102 5105 I-upper_bound

The 0 3 5106 5109 O
participant 4 15 5110 5121 O
may 16 19 5122 5125 O
be 20 22 5126 5128 O
receiving 23 32 5129 5138 O
ongoing 33 40 5139 5146 O
therapy 41 48 5147 5154 B-treatment
with 49 53 5155 5159 I-treatment
trastuzumab 54 65 5160 5171 I-treatment
and/or 66 72 5172 5178 O
pertuzumab 73 83 5179 5189 B-treatment
at 84 86 5190 5192 O
the 87 90 5193 5196 O
time 91 95 5197 5201 O
of 96 98 5202 5204 O
study 99 104 5205 5210 O
entry 105 110 5211 5216 O

The 0 3 5217 5220 O
participant 4 15 5221 5232 O
must 16 20 5233 5237 O
have 21 25 5238 5242 O
an 26 28 5243 5245 O
estimated 29 38 5246 5255 O
left 39 43 5256 5260 B-clinical_variable
ventricular 44 55 5261 5272 I-clinical_variable
ejection 56 64 5273 5281 I-clinical_variable
fraction 65 73 5282 5290 I-clinical_variable
( 74 75 5291 5292 I-clinical_variable
LVEF 75 79 5292 5296 I-clinical_variable
) 79 80 5296 5297 I-clinical_variable
within 81 87 5298 5304 O
the 88 91 5305 5308 O
normal 92 98 5309 5315 O
range 99 104 5316 5321 O
by 105 107 5322 5324 O
either 108 114 5325 5331 O
echocardiogram 115 129 5332 5346 B-treatment
or 130 132 5347 5349 O
multigated 133 143 5350 5360 B-treatment
acquisition 144 155 5361 5372 I-treatment
( 156 157 5373 5374 I-treatment
MUGA 157 161 5374 5378 I-treatment
) 161 162 5378 5379 I-treatment
scan 163 167 5380 5384 I-treatment

The 0 3 5385 5388 O
participant 4 15 5389 5400 O
must 16 20 5401 5405 O
have 21 25 5406 5410 O
an 26 28 5411 5413 O
estimated 29 38 5414 5423 O
left 39 43 5424 5428 B-clinical_variable
ventricular 44 55 5429 5440 I-clinical_variable
ejection 56 64 5441 5449 I-clinical_variable
fraction 65 73 5450 5458 I-clinical_variable
within 74 80 5459 5465 O
the 81 84 5466 5469 O
normal 85 91 5470 5476 O
range 92 97 5477 5482 O
by 98 100 5483 5485 O
either 101 107 5486 5492 O
echocardiogram 108 122 5493 5507 B-treatment
or 123 125 5508 5510 O
multigated 126 136 5511 5521 O
acquisition 137 148 5522 5533 O
( 149 150 5534 5535 O
MUGA 150 154 5535 5539 O
) 154 155 5539 5540 O
scan 156 160 5541 5545 O

The 0 3 5546 5549 O
participant 4 15 5550 5561 O
should 16 22 5562 5568 O
remain 23 29 5569 5575 O
on 30 32 5576 5578 O
the 33 36 5579 5582 O
current 37 44 5583 5590 O
endocrine 45 54 5591 5600 B-treatment
therapy 55 62 5601 5608 I-treatment
while 63 68 5609 5614 O
receiving 69 78 5615 5624 O
abemaciclib 79 90 5625 5636 B-treatment

Untreated 0 9 5637 5646 O
CNS 10 13 5647 5650 B-cancer
metastases 14 24 5651 5661 I-cancer

peripheral 0 10 5662 5672 B-chronic_disease
neuropathy 11 21 5673 5683 I-chronic_disease

residual 0 8 5684 5692 O
alopecia 9 17 5693 5701 B-chronic_disease

the 0 3 5702 5705 O
participant 4 15 5706 5717 O
may 16 19 5718 5721 O
have 20 24 5722 5726 O
received 25 33 5727 5735 O
prior 34 39 5736 5741 B-treatment
systemic 40 48 5742 5750 I-treatment
chemotherapy 49 61 5751 5763 I-treatment
in 62 64 5764 5766 O
the 65 68 5767 5770 O
neoadjuvant 69 80 5771 5782 B-treatment
or 81 83 5783 5785 O
adjuvant 84 92 5786 5794 B-treatment
setting 93 100 5795 5802 I-treatment

